Prof Andrea Necchi speaks to ecancer about the primary and subgroups analyses by PD-L1 status of cohort B of the phase 2 KEYNOTE-057 trial. The study investigated pembrolizumab monotherapy for participants with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC).
Prof Necchi explains the background and study design. The study found that after 45 months of follow-up, pembrolizumab showed anti-tumour activity in the total population and across PD-L1 subgroups in patients with BCG-unresponsive papillary-only HR NMIBC who declined or were ineligible for radical cystectomy.
Prof Necchi concludes by discussing the impact of these results on clinical practice.